Advertisement

U.S. Markets open in 45 mins

S&P Futures
5,893.50
-3.00(-0.05%)
Dow Futures
43,476.00
-92.00(-0.21%)
Nasdaq Futures
20,523.25
+29.50(+0.14%)
Russell 2000 Futures
2,316.00
+2.40(+0.10%)
Crude Oil
67.45
+0.43(+0.64%)
Gold
2,606.00
+35.90(+1.40%)

Adicet Bio, Inc. (ACET)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

0.9469

-0.1031

(-9.82%)

At close: 04:00PM EST

1.0399

+0.09

(+9.82%)

Pre-Market:

08:00AM EST

Trade prices are not sourced from all markets

All

Business Wire
Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
REDWOOD CITY, Calif. & BOSTON, November 18, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first LN patient has been dosed in the Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases.
Simply Wall St.
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...